By Josh BeckermanSangamo Therapeutics Inc. shares were down 8% to $1.84 after hours as the company said Novartis AG and Biogen Inc. terminated collaboration and license agreements. Sangamo and Novartis said in July 2020 that they would collaborate on gene regulation therapies to address three neurodevelopmental targets, including autism spectrum disorder.

Source: Wall Street Journal March 18, 2023 10:47 UTC